The Role of the JAK-STAT Pathway in Childhood B-Cell Acute Lymphoblastic Leukemia.
Karolina Joanna ZiętaraKinga WróblewskaMonika ZajączkowskaJoanna TaczałaMonika LejmanPublished in: International journal of molecular sciences (2024)
B-cell lymphoblastic leukemia is a hematologic neoplasm that poses a serious health concern in childhood. Genetic aberrations, such as mutations in the genes IL-7, IL7R, JAK1, JAK2, TLSP , CRLF2 , and KTM2A or gene fusions involving BCR :: ABL1 , ETV6 :: RUNX1 , and PAX5 :: JAK2 , often correlate with the onset of this disease. These aberrations can lead to malfunction of the JAK-STAT signaling pathway, which is implicated in various important biological processes, including those related to immunology. Understanding the mechanisms underlying the malfunction of the JAK-STAT pathway holds potential for research on drugs targeting its components. Available drugs that interfere with the JAK-STAT pathway include fludarabine, ruxolitinib, and fedratinib.
Keyphrases
- acute lymphoblastic leukemia
- copy number
- genome wide
- signaling pathway
- healthcare
- allogeneic hematopoietic stem cell transplantation
- public health
- tyrosine kinase
- acute myeloid leukemia
- epithelial mesenchymal transition
- chronic myeloid leukemia
- mental health
- early life
- pi k akt
- cancer therapy
- low grade
- drug delivery
- social media
- young adults